139 filings
8-K
FGEN
FibroGen Inc
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
8-K
FGEN
FibroGen Inc
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
FGEN
FibroGen Inc
27 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
FGEN
FibroGen Inc
5 Oct 23
Departure of Directors or Certain Officers
7:41pm
8-K
FGEN
FibroGen Inc
6 Sep 23
Departure of Directors or Certain Officers
8:55am
8-K
gxyp7l snsttew09b
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
xwh5q
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
8l1u5gcv
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
3swv ugfq6yhtml5dxax
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
ynu9sxcju4h s1b
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
d3qv1i8
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
e0lvymq1
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
237olqci
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
7m647b1uq62qa 87h
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm
8-K
r0kdub
1 May 23
Entry into a Material Definitive Agreement
4:48pm
8-K
fg2cz3wm
27 Feb 23
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
4:06pm
8-K
u6wop88l1zoqm3m5v
7 Nov 22
FibroGen Reports Third Quarter 2022 Financial Results
4:06pm
8-K
2uf53zaxhvtmyd50e8
8 Aug 22
FibroGen Reports Second Quarter 2022 Financial Results
4:07pm
8-K
gmskjlq9
17 Jun 22
Submission of Matters to a Vote of Security Holders
5:20pm
8-K
ns0oz1p oa
8 Jun 22
Departure of Directors or Certain Officers
4:06pm